Cargando…
Raltegravir does not revert efflux activity of MDR1-P-glycoprotein in human MDR cells
BACKGROUND: Raltegravir (Isentress®)(RALT) has demonstrated excellent efficacy in both treatment-experienced and naïve patients with HIV-1 infection, and is the first strand transfer integrase inhibitor to be approved for use in HIV infected adults worldwide. Since the in vivo efficacy of this class...
Autores principales: | Dupuis, Maria Luisa, Ascione, Alessandro, Palmisano, Lucia, Vella, Stefano, Cianfriglia, Maurizio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3852167/ https://www.ncbi.nlm.nih.gov/pubmed/24053678 http://dx.doi.org/10.1186/2050-6511-14-47 |
Ejemplares similares
-
HIV-1 integrase inhibitors are substrates for the multidrug transporter MDR1-P-glycoprotein
por: Cianfriglia, Maurizio, et al.
Publicado: (2007) -
Small and Innovative Molecules as New Strategy to Revert MDR
por: Zinzi, Laura, et al.
Publicado: (2014) -
Expression of MDR1/P glycoprotein in human sarcomas.
por: Vergier, B., et al.
Publicado: (1993) -
Clinical development of monoclonal antibody-based drugs in HIV and HCV diseases
por: Flego, Michela, et al.
Publicado: (2013) -
A Novel MFS-MDR Transporter, MdrP, Employs D223 as a Key Determinant in the Na(+) Translocation Coupled to Norfloxacin Efflux
por: Zhang, Rui, et al.
Publicado: (2020)